Drugs / ZSNeo-DC1.1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06253234 | Feb 2024 → Jun 2025 overdue | grade III glioma | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07365280 | Jan 2026 → Dec 2028 expected | glioblastoma | ZSky Biotech Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZSNeo-DC1.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07365280 ↗ |
| Modality | Cell therapy | “autologous genetic-modification-free DC cells” NCT06253234 ↗ |
| Route | Subcutaneous | “six subcutaneous injections of ZSNeo-DC1.1” NCT07365280 ↗ |